home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  May 24, 2024
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 461 active entries

Replicor Inc.

6100, avenue Royalmount
Montreal, QC, H4P 2R2

Phone: 514-496-9011
Fax: 514-496-9021

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Replicor is developing a new drug that will revolutionize the treatment of patients with chronic hepatitis B which affects up to 350 million patients worldwide. By blocking the release of a viral protein called HBsAg, our drug allows the re-establishment of a proper immune response to the infection and results in a high proportion of patients achieving long term immunological control over their infection.

The efficacy and safety of our drug has already been successfully demonstrated in a randomized phase II human clinical trial. Based on Replicor's current clinical trial results, it is projected that a functional control rate of 80% will be achieved when our drug is used in combination with currently available approved drugs. The most effective treatment to date can only achieve a rate of functional control less than 10 %.

Co-infection with hepatitis B and hepatitis D affects 15-20 million patients worldwide and is the most aggressive form of viral hepatitis leading to a high rate of cirrhosis. No drug has been approved for this condition making this an orphan drug indication with the possibility of accelerated approval by the FDA and EMA. We have demonstrated in a recent proof of concept clinical trial published in The Lancet Gastroenterology & Hepatology, that 7 patients out of 11 have completely eliminated the HDV virus from their blood when receiving our drug in combination with Pegasys making our drug the most promising asset in this field.

Longer treatment durations are expected to achieve higher rates of cure for this condition.

Selected Categories:

Product Company   Service Company
- Research
- Research
- Research

Last update of this entry: December 07, 2021

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2024 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.